Co-Own the Patent

In June 2016, Vivasolis has been executed an exclusive license agreement with academic to develop the brand new human derived antibody as a targeted immunotherapy for chronic disease. Under the agreement, Vivasolis has acquired the exclusive rights to all intellectual property, including relevant patents, related to M Factor antibodies as the chronic disease therapy. Vivasolis is based on the innovative science developed by the professional team with both academic and industry experimence. Vivasolis had been co-own the patent with acamedia since October 2017 base on the achivement of industry-university cooperative research.